Clinical trial · Interventional
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine
Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine: a Randomized, Double-blind, Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to test the effect of nebulized lidocaine on the hemodynamic response in the participant undergoing double-lumen endotracheal intubation. The main question it aims to answer is to evaluate the changes in mean arterial pressure after intubation. Participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation. Researchers will compare saline group to see if saline effects
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine | Drug | — | UNRESOLVED |
| Saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- lidocaine
- description
- Intervention group
- interventionNames
- Drug: Lidocaine
- type
- PLACEBO_COMPARATOR
- label
- saline
- description
- control group
- interventionNames
- Drug: Saline
Primary outcomes (1)
- measure
- mean arterial pressure after intubation
- timeFrame
- Immediately after intubation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged 18-65 years, American Society of Anesthesiologists class I-II 2. participants undergoing double-lumen endotracheal intubation under general anesthesia 3. signed informed consent and volunteered to participate in the experiment Exclusion Criteria: 1. Poor control of hypertension 2. preoperative arrhythmia 3. severe coronary artery or heart valve disease 4. sequelae of cerebrovascular accident 5. severe lung, liver, kidney and immune system diseases 6. Suspected difficult airway 7. confirmed or suspected allergy to this trial drug 8. As judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)
References
Publications (0)
Data not yet available